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Abstract
Background: Reactivation of chronic Chagas disease, which occurs in approximately 20% of patients coinfected with HIV/
Trypanosoma cruzi (T. cruzi), is commonly characterized by severe meningoencephalitis and myocarditis. The use of
quantitative molecular tests to monitor Chagas disease reactivation was analyzed.
Methodology: Polymerase chain reaction (PCR) of kDNA sequences, competitive (C-) PCR and real-time quantitative (q) PCR
were compared with blood cultures and xenodiagnosis in samples from 91 patients (57 patients with chronic Chagas
disease and 34 with HIV/T. cruzi coinfection), of whom 5 had reactivation of Chagas disease and 29 did not.
Principal Findings: qRT-PCR showed significant differences between groups; the highest parasitemia was observed in
patients infected with HIV/T. cruzi with Chagas disease reactivation (median 1428.90 T. cruzi/mL), followed by patients with
HIV/T. cruzi infection without reactivation (median 1.57 T. cruzi/mL) and patients with Chagas disease without HIV (median
0.00 T. cruzi/mL). Spearman’s correlation coefficient showed that xenodiagnosis was correlated with blood culture, C-PCR
and qRT-PCR. A stronger Spearman correlation index was found between C-PCR and qRT-PCR, the number of parasites and
the HIV viral load, expressed as the number of CD4
+ cells or the CD4
+/CD8
+ ratio.
Conclusions: qRT-PCR distinguished the groups of HIV/T. cruzi coinfected patients with and without reactivation. Therefore,
this new method of qRT-PCR is proposed as a tool for prospective studies to analyze the importance of parasitemia
(persistent and/or increased) as a criterion for recommending pre-emptive therapy in patients with chronic Chagas disease
with HIV infection or immunosuppression. As seen in this study, an increase in HIV viral load and decreases in the number of
CD4
+ cells/mm
3 and the CD4
+/CD8
+ ratio were identified as cofactors for increased parasitemia that can be used to target
the introduction of early, pre-emptive therapy.
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Introduction
Chagas disease is endemic in Latin America, where fewer than 8
million people, many of whom live in urban centers, are infected
by T. cruzi [1]. In Brazil, the control of the Chagas disease insect
vector Triatoma infestans and prevention of the transmission of T.
cruzi parasitosis by blood transfusion have led to epidemiologic
changes, shifting the predominant T. cruzi transmission routes to
oral, congenital, and organ transplant transmission. HIV/T. cruzi
coinfection has been found in urban centers, and HIV infection
[2] has spread to regions in which Chagas disease is endemic. In
addition, Chagas disease is now an emerging disease in developed
countries, with active congenital and organ transplant transmission
and reactivation of the chronic disease [3,4].
Acute Chagas disease is characterized by high levels of
parasitemia, which is detected by direct microscopy of fresh buffy
coat, a quantitative buffy coat (QBC) test, or a microhematocrit
test [5,6]. In the chronic disease, low-level parasitemia is observed
and can be detected only by indirect parasitological methods
(xenodiagnosis and blood culture) [7]. Anti-T. cruzi IgG antibodies
are found in almost 100% of these patients [8]. Most chronically
infected patients do not develop clinical symptoms of Chagas
disease, but approximately 20–30% suffer from heart and or
digestive tract disease [8].
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parasitemia levels in HIV coinfected patients than in those with
chronic Chagas disease alone [9,10]. Reactivation of chronic
Chagas disease, which occurs in approximately 20% of individuals
coinfected with HIV/T. cruzi, is characterized by high parasitemia
levels, similar to an acute infection [11]. More severe disease
(meningoencephalitis and/or myocarditis) has been commonly
described in patients infected with HIV/T. cruzi [12–15]; the
involvement of other organs, such as the skin [16], gastrointestinal
tract, and pericardium, has also been reported [14]. The diagnosis
of Chagas disease reactivation is based on direct observation
methods [5,6]. However, this diagnosis is not usually made during
the early phase of reactivation, and many patients die soon after
diagnosis or during treatment [11]. Case fatality is higher in
patients with late diagnosis of reactivation because they die soon
after the introduction of the therapy [6,8–12].
Sensitive and rapid methods are required to monitor parasit-
emia in immunosuppressed patients with Chagas disease.
Xenodiagnosis and blood culture are highly sensitive for the acute
disease but are labor-intensive and time-consuming methods and
the results take 30–120 days to be analyzed. In addition, technical
expertise is required to manipulate live parasites, due to the risk of
infection of laboratory staff [7,9,17]. In HIV/T. cruzi-infected
patients, semi-quantitative xenodiagnosis that indicates the
percentage of nymphs per assay may predict the occurrence of
Chagas disease reactivation. Episodes of reactivation have been
observed in 50% of patients who show $20% nymphs per assay in
a follow-up period of 5 years [11].
A competitive polymerase chain reaction (C-PCR) method
[18,19] has been reported for monitoring the treatment of children
with congenital Chagas disease, patients with chronic Chagas
heart disease, and a patient with HIV and meningoencephalitis. It
was used to demonstrate clearance or early detection of the
parasite [19–21]. Another molecular method, quantitative real-
time PCR (qRT-PCR), has been used to diagnose congenital
[22,23] and chronic Chagas disease and showed 41% positive
detection of the chronic disease [22]. Using this method, low
parasitemia was found in mothers (93.3%,10 parasites/mL) and
higher parasitemia was found in neonates (76.3%.1,000 para-
sites/mL) [23]; parasitemia correlated negatively with age (0.01–
640 parasites/mL) [24].
The aim of this study was to evaluate the use of a new
quantitative molecular method (qRT-PCR) to monitor T. cruzi
parasitemia in HIV-infected patients with or without Chagas
disease reactivation. In addition, the sensitivities of different
molecular and parasitological tests were compared.
Methods
Participants
The study included 91 samples that were collected between
1996 and 2008 from patients $18 years old with Chagas disease
who were admitted to the AIDS Clinic and/or Clinic of Infectious
and Parasitic Diseases at the Hospital das Clinicas, a tertiary
hospital attached to the School of Medicine of the University of
Sa ˜o Paulo, Brazil. The patients were classified into two groups: (1)
57 immunocompetent patients with chronic Chagas disease (CR)
and (2) 34 patients with chronic Chagas disease coinfected with
HIV, of whom 29 lacked reactivation (CO) and 5 had reactivation
of Chagas disease (RE). The inclusion criterion for patients with
Chagas disease with or without HIV infection was the presence of
antibodies in two or three conventional serological tests for Chagas
disease (indirect immunofluorescence ($1/40), indirect hemag-
glutination ($1/40) or Enzyme linked immunoassay (ELISA))
[24]. HIV patients were included after detection of anti-HIV
antibodies by ELISA and confirmation by immunoblot [25].
Chagas disease reactivation was diagnosed if at least one of the
following tests was positive: direct blood microscopy or QBC for
T. cruzi (two patients) or direct cerebrospinal fluid (CSF)
examination for T. cruzi (three patients). A control group of 58
healthy individuals without Chagas disease (indicated by negative
conventional serological tests for Chagas disease) was used to
check for contamination during the sample extraction process; the
control samples were paired with samples from patients.
Direct and indirect parasitological assays
Trypomastigotes were identified by direct microscopy of
peripheral blood mononuclear cells (PBMCs) or through QBC
analysis [6]. For QBC, the blood was collected in a microhemat-
ocrit tube containing acridine orange (BD Biosciences). After
centrifugation, the parasites remaining in the platelet layer at the
top of the buffy coat were identified by immunofluorescence
microscopy. The blood culture assay was performed as previously
described [17]. Six culture tubes were examined after 10, 20, 30,
60, 90 and 120 days of culture. The results are expressed as the
number of positive tubes divided by the total number of tubes
examined (% positive tubes); the result was considered positive if
any tube was positive and negative if all were negative.
Xenodiagnosis was performed with 20–40 nymphs of T. infestans
fed in vitro with 10 mL of patient blood. The search for T. cruzi in
the gut contents of each triatome was performed 30, 60 and 90
days later and the results are expressed as the percentage of
positive insects (semi-quantitative xenodiagnosis); or a positive
result if at least one insect was positive and negative if all of them
were negative [7,26].
Sample preparation and DNA extraction
DNA was extracted with QIAamp
TM DNA Mini Kit (Qiagen,
Hilden, Germany) from whole blood collected in 6 M guanidine
HCl plus 0.2 M EDTA buffer (pH 8); in a few cases, DNA was
extracted from blood collected in EDTA (PBMC) or from CSF,
which was collected from two patients with central nervous system
reactivation, as previously reported [27,28]; samples were stored at
220uC. The quantity and purity of the DNA were determined
with a spectrophotometer (Gene-Quant, Pharmacia Biotech,
Cambridge, England), and only samples with high purity were
used in the experiments.
Author Summary
Chagas disease is endemic in Latin America and is caused
by the flagellate protozoan T. cruzi. The acute phase is
asymptomatic in the majority of the cases and rarely
causes inflammation of the heart or the central nervous
system. Most infected patients progress to a chronic
phase, characterized by cardiac or digestive involvement
when not asymptomatic. However, when patients are also
exposed to an immunosuppressant (such as chemother-
apy), neoplasia, or other infections such as HIV, T. cruzi
infection may develop into a severe disease (Chagas
disease reactivation) involving the heart and central
nervous system. The current microscopic methods for
diagnosing Chagas disease reactivation are not sensitive
enough to prevent the high rate of death observed in
these cases. Therefore, we propose a quantitative method
to monitor blood levels of the parasite, which will allow
therapy to be administered as early as possible, even if the
patient has not yet presented symptoms.
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PCR was performed using the S35 and S36 primer pair, which
amplifies a 330-bp minicircle sequence from T. cruzi (Gibco
TM Life
Technologies, CA, USA) [29]. The reactions contained Taq
polymerase, 0.2 mM of each primer, 1.4 mM MgCl2 and 50–
150 ng of DNA. Negative controls for the master mix preparation
and DNA addition and a positive control, which consisted of
2610
215 mg of DNA from the Y strain of T. cruzi, were used. The
presence of inhibitors of DNA amplification was verified by b-
actin amplification and by amplification of duplicate patient
samples containing parasite DNA. To assess the analytical
sensitivity of the qualitative PCR assays, 10-fold dilutions from
0.2 pg to 0.002 fg of DNA parasites were processed; the detection
limit of the assay was 0.2 fg of T. cruzi, which corresponded to 0.01
parasite/assay in an agarose gel.
Competitive PCR
A 280 bp DNA fragment with binding sites for the S34/S35
oligonucleotides was used for competitive PCR with the kDNA
330 bp product and was cloned into the pT7 Blue vector (kindly
provided by the Laborato ´rio Multidisciplinar de Pesquisa em Doenc ¸a
deChagas,UniversidadedeBrası ´lia).The assay was performed in the
Laboratory of Immunology, Faculdade de Medicina da USP, as
previously described [18]. Known concentrations of the competitor
(150, 15, 1.5 and 0.15 fg), or no competitor, were mixed with four
aliquots of DNA from patient samples that had previously shown
positive PCR results for kDNA. For each competitive PCR analysis,
we included five samples per patient.
The equivalence point was determined by visually comparing
the intensities of the 280 and 330 bp products. The number of T.
cruzi/mL of blood was calculated based on the blood volume used
for extraction, the dilution of the sample, and the amount of
patient DNA used in the PCR reaction.
Real-time PCR
PCR for the microsatellite sequence TCZ3/TCZ4 (TGCTG-
CAGTCGGCTGATCGTTTTCGA/CAAGCTTGTTTGGT-
GTCCAGTGTGTGA), which was previously described by Ochs
et al. (1996) [30] as internal primers for TCZ1 and TCZ2 (Gibco
TM
Life Technologies, CA, USA), was performed using 20 mlS Y B R
TM
Advantage
TMqRT-PCRPremix(Clontech,CA,USA),accordingto
the manufacturer’s instructions. The mixture contains Taq polymer-
ase, 0.2 mM of each primer, 1.4 mM MgCl2 and 50–150 ng of
DNA. We amplified a 149 bp sequence using 45 PCR cycles with a
denaturation temperature of 94uC, an annealing temperature of
64uC and an extension temperature of 72uC on a RotorGene
3000
TM (Corbett Research, Australia).
All DNA extractions and amplification reactions were per-
formed with the appropriate negative controls to detect contam-
ination at any stage of the procedure and with positive controls
that gave reproducible results during all of the experiments.
The standard amplification curve was prepared from 10-fold
dilutions of DNA from blood spiked with 5610
5 to 5610
23 T.
cruzi epimastigotes/mL. Y strain (human, Brazil). The detection
limit was found at 0.005 parasite/mL (Figure 1). The initial
number of parasites (10
7/mL) was counted by microscopic
examination (Neubauer camera). The first blood aliquot mixed
with Guanidine HCl-EDTA (v/v) was spiked with 5.10
5 parasites
cells/mL. After homogenization, this tube was used as starter for
preparing 10 ten-fold serial dilutions ranging from 5610
5 to
5610
23 T. cruzi epimastigotes/mL.
The final concentration of the patient sample was calculated
based on the volume of the blood extracted, the amount of DNA
amplified and the volume and dilution of the sample analyzed.
Dilution of the samples was necessary for patients with reactivation
and for some coinfected patients with large numbers of parasites.
High levels of parasitemia were used for comparison among the
different methods or groups but were not necessarily indicative of
reactivation. Three trained individuals performed and read the
tests (one was responsible for the xenodiagnosis, one for the
hemoculture and the other for the molecular tests). The results
were read blind.
Viral load
The HIV plasma viral load was determined by reverse-
transcriptase (RT)-PCR using an Amplicor
TM HIV-1 Monitor
Test (Roche Diagnostic Systems, NJ, USA) in the Central
Laboratory of Hospital das Clı ´nicas da Faculdade de Medicina
da Universidade de Sa ˜o Paulo, which had a lower detection limit
of 200 copies of HIV/mm
3.
CD4
+ and CD8
+ counts
CD4
+ and CD8
+ T lymphocyte counts were determined by flow
cytometry (FACSCalibur, BD Biosciences, CA, USA) using
antibodies to CD4 and CD8 (BD Biosciences).
Ethics
All protocols were approved by the ethical committee
(Comissa ˜o de E ´tica para Ana ´lise de Projetos de Pesquisa -
CAPPesq), Hospital das Clı ´nicas, Faculdade de Medicina of
University of Sa ˜o Paulo. Written informed consent was obtained
from all participants.
Statistical analysis
SPSS version 17 was used for the statistical analyses. The chi-
squared test and Fisher exact test were used to compare the
qualitative results of the tests and the differences between the
patient groups. The McNemar test was used for comparisons
between paired proportions. For non-parametric data, Spearman’s
rank correlation coefficient was used for quantitative variables
(P,0.01) [31]. Kruskal–Wallis one-way analysis of variance was
also applied to non-parametric data to compare the three groups
of patients, followed by the comparison of independent groups,
two by two, by the Dunn’s Multiple Comparison post test (Prism
3.0, Graph Pad Software Incorporation, CA, California). P
values,0.05 were considered significant.
Results
Demographic characteristics
There were no significant differences in gender (CR male
frequency=38.6%; CO male frequency=48.3%; RE male frequen-
cy=60.0%) among the groups with and without HIV infection. The
five individuals with chronic Chagas disease, HIV infection and
reactivation of Chagas disease were younger than those without
HIV infection (CR mean=46.1612.2 years, median=43; CO
mean=42.0610.1, median=38; RE mean=32.763.93, medi-
an=33) (P=0.014).
Qualitative tests: PCR, blood culture, and xenodiagnosis
A comparison of the different tests for the HIV-positive and
HIV-negative patients is shown in Table 1. PCR with the S35/36
primers was more sensitive than blood culture, xenodiagnosis and
both tests combined (P,0.001). Patients with HIV infection
(CO+RE) showed higher rates of positive results by PCR
(P,0.001, Fisher exact test), xenodiagnosis (P,0.001, Fisher exact
test) or both tests (P=0.002, x
2) compared with patients without
qPCR and Chagas Disease Reactivation
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per assay 6 SD (Table 2) was observed in the RE group (Kruskal-
Wallis, P=0.001).
Quantitative tests
Competitive PCR. The semi-quantitative assay was
performed on 38 samples with positive S35/36 PCR results: 17
CR, 16 CO and 5 RE (Figure 2A). A higher number of copies was
observed in patients with coinfection and Chagas disease
reactivation, followed by the group with both infections but no
reactivation and chronic Chagas disease patients without HIV
infection (Table 2). The test was not performed on all samples
because it requires a large amount of purified DNA, which was not
always available in the amount necessary for the second
measurement required when the equivalence point could not be
determined.
Real-time PCR. The standard amplification curve was
prepared from 10-fold dilutions of DNA from blood spiked with
5610
5 to 5610
23 epimastigotes/mL. Figure 1 A shows the limit of
detection 0.005 parasite/mL, found by Probit analysis; the slope
was 23.2, the reaction efficiency was 1.05, and the linear
regression curve showed R2=0.986 (Figure 1B) and
Tm=89.6660.25uC (Figure 1C). This assay was reproducible at
$0.005 parasite/mL, as observed by Ct and Tm values in 5
different assays using triplicates and duplicates. Amplification
products from patient samples with low parasitemia and doubtful
melting temperature were analyzed by agarose gel electrophoresis
to check the size of the expected 149 bp product (data not shown).
All91patients with Chagasdisease with orwithout HIVinfection
were analyzed by qualitative PCR and qRT-PCR (one sample per
patient) – Table 1, 2 and 3. Forty nine patients showed positive
results by qualitative and quantitative PCR. A comparison between
the qualitative PCR and qRT-PCR results showed undetectable
parasitemia in 12.09% of samples by qRT-PCR and 4.39% only by
S35/S36 PCR despite the positive result by other test.
The level of parasitemia, expressed as DNA copies/mL, was
highest in the RE group, followed by CO and CR (Figure 2B,
Table 2). In the CSF of two patients with HIV/T. cruzi coinfection
and Chagas disease reactivation, the number of parasite copies
was greater than 5610
5 copies/mL.
Patients in the HIV/T. cruzi–coinfected group without Chagas
disease reactivation presented different levels of parasitemia
(Table 2); the majority were similar to the chronic cases, but a
small portion (,10.0%) had the highest levels in this group, and
the remainder had intermediate levels (data not shown).
The amplification of T. cruzi DNA extracted from the blood of
four patients with HIV/T. cruzi coinfection (CO) is shown in
Figure 3.
Figure 1. Standardization of qRT-PCR using the SYBR Green system. A) Standard amplification curve generated by10 fold serial dilutions of
DNA from blood spiked with T. cruzi epimastigotes DNA (from 5.10
4 to 5.10
23 parasites/mL) and negative controls, threshold=0.12, efficiency=1.05.
C) Linear regression curve and regression coefficient, R
2=0.986. B). Melting curve analysis of amplicons of samples represented in A:
Tm=89.6660.25uC.
doi:10.1371/journal.pntd.0001277.g001
Table 1. Sensitivities of the qualitative PCR
a, xenodiagnosis
b
and blood culture
c in Chagas disease with/without HIV
infection.
Group
d
S35/36
PCR, % (n)
XD,
%( n)
BC,
%( n)
(XD and/
or BC), % (n)
CR 50.9 (57) 9.3 (54) 31.6 (57) 33.3 (57)
CO 89.7 (29) 44.8 (29) 35.7 (28) 58.6 (29)
RE 100.0 (5) 60.0 (5) 100.0 (5) 100.0 (5)
Total 65.9 (91) 23.9 (88) 36.7 (90) 54.9 (91)
aqualitative S35/36 PCR,
bxenodiagnosis (XD),
cblood culture (BC),
dgroups of patients: chronic Chagas disease with (CO) and without HIV infection
(CR) and reactivation of Chagas disease in HIV infected patients (RE).
Xenodiagnosis was not performed on three samples from chronic chagasic
patients. Blood culture was not performed on one sample from co-infected
patient.
doi:10.1371/journal.pntd.0001277.t001
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Table 3 shows the Spearman correlation indices (rs) of the
quantitative molecular, parasitological and immunological tests. A
strong positive correlation between the number of parasites/mL
detected by C-PCR and qRT-PCR was shown in Figure 4.
To study the influence of CD4
+ and CD8
+ T cells on the level of
parasitemia, we calculated the Spearman correlation coefficient
for 30 samples from patients infected with HIV/T. cruzi with and
without parasite reactivation and found negative correlations with
the number of CD4
+ T cells (data not shown) and the CD4
+/
CD8
+ ratio (Figure 5). However, no correlation was observed with
the number of CD8
+ T cells (data not shown).
A positive correlation was found between the HIV viral load
and the level of T. cruzi parasitemia in 20 samples from individuals
infected with HIV/T. cruzi with and without Chagas disease
reactivation (Figure 6).
Discussion
In this study, the utility of the molecular methods C-PCR and
qRT-PCR for the diagnosis and quantification of the number of
Table 2. Results of xenodiagnosis
a, C-PCR
b and qRT-PCR
c in the three groups of patients
d (CO, CR, RE).
Variable CR CO RE
aXD mean % of nymphs 6 SD 1.1564.02 3.5466.10 31.70636.53
XD median % of nymphs 0.0 0.0 24.3
XD min-max % nymphs 0.0–21.0 0.0–28.6 0.0–86.7
C-PCR mean n
o of parasites 6 SD 20.73630.74 964.0661685.82 16500.00619006.58
C-PCR median n
o of parasites 14.07 175.00 10000.00
C-PCR min-max n
o of parasites 0.0–125.0 0.0–5000.0 5000.0–50000.0
qRT-PCR CT mean 6 SD 33.8360.49 31.4160.70 24.3062.12
qRT-PCR CT min-max 28.29–37.30 25.30–37.10 18.36–31.38
qRT-PCR mean n
o of parasites 6 SD 0.4460.20 10.4363.53 12584.96611368.35
qRT-PCR median n
o of parasites 0.00 1.57 1428.90
qRT-PCR min-max n
o of parasites 0.00–10.98 0.00–70.00 109.20–58000.00
aXD - Xenodiagnosis (% of nymphs positive per assay) was performed in 90 patients,
bC-PCR (number of parasites) in 38 patients and
cqRT-PCR in 91 patients (Ct for 53 positive samples and number of parasites for 91 patients=91 samples),
dgroups of patients: chronic Chagas disease with (CO, 29 patients) and without HIV infection (CR, 57 patients) and reactivation of Chagas disease in HIV infected patients
(RE, 5 patients).
doi:10.1371/journal.pntd.0001277.t002
Figure 2. C-PCR and qRT-PCR in the blood of patients’ groups (CR, CO and RE). A) Number of T. cruzi/mL (log10) in blood by C-PCR. CR
(n=17); CO (n=16) and RE (n=5). The line represents the median. Comparative analysis among the groups showed a statistically significant
difference (P,0.001) by Kruskal–Wallis test. Comparing the groups, a statistically significant difference was observed between CR6CO, P,0.001;
CR6RE, P,0.001; and CO6RE, P.0.05) (Dunn s Multiple Comparison test). B) Number of T. cruzi/mL (log10) in blood by qRT-PCR. CR (n=57); CO
(n=29) and RE (n=5). Comparison of the qRT-PCR results observed in the three groups of patients with Chagas disease. The results revealed a
statistically significant difference (P,0.001) by Kruskal–Wallis test, and comparison between the groups showed statistically significant differences
between CR6CO (P,0.001), CR6RE (P,0.001), and CO6RE, (P,0.05) (Dunn’s Multiple Comparison test).
doi:10.1371/journal.pntd.0001277.g002
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coinfection was demonstrated for the first time.
In addition, we have shown that qRT-PCR was able to dis-
tinguish between the groups of HIV/T. cruzi–infected patients with
and without Chagas disease reactivation and between groups of
patients with chronic Chagas disease and those coinfected with
HIV/T. cruzi, with or without Chagas disease reactivation (Figure 2
B and Table 2).
High levels of parasitemia have been reported in three chronic
heart disease patients after heart transplantation [24], but no
report has compared parasitemia in reactivated and non-
reactivated HIV/T. cruzi-infected groups. The inclusion of the
latter group indicated that there are different levels of parasitemia
in these patients. The majority had similar levels to the chronic
cases, less than 10% had the highest levels of the group and the
remainder showed intermediate levels of parasitemia. The patients
with higher parasitemia might be targeted for therapy.
Additionally, unlike what we would expect based on the
immunopathogenesis of HIV/T. cruzi coinfection, we found that
one HIV-infected patient with reactivation had much lower
parasitemia than the majority of the RE group. This episode of
reactivation was characterized by the presence of trypomastigotes,
as detected by direct microscopy of the blood [32]. The patient
only presented mild symptoms without meningoencephalitis,
myocarditis or other tissular lesions. The level of CD4
+ T cells
was more than 300/mm
3, and, during this period, the patient
showed .20% of nymphs on xenodiagnosis and an increased viral
load. The lineage type of the parasite was no different from the
majority of the cases. It is possible that the level of parasitemia and
the level of CD4
+/mm
3 did not change because the reactivation
was diagnosed in the initial phase of the disease and early therapy
with benznidazole was administered. Although the number of
patients with reactivation was small, the high number of DNA
copies observed in the blood (Figure 2B) or cerebrospinal fluid of
the remaining RE patients with myocarditis or meningoenceph-
alitis is impressive. In our study, qRT-PCR showed high
performance with a low detection limit (0.005 parasite/mL) and
good efficiency, as previously described [32–34]. We suggest that
increasing parasitemia in subsequent examinations and/or
stabilization at levels higher than previously seen in the same
patient should be carefully monitored for CD4
+ counts and viral
load.
The two quantitative molecular methods, C-PCR and qRT-
PCR, used in the present study were strongly correlated by
Table 3. Spearman’s rank correlation coefficients observed between tests: blood culture, xenodiagnosis, competitive PCR,
quantitative real-time PCR.
Methods (quantification method)
a Spearman rs P Samples (n)
XD6BC
b (% nymphs +)6(% tubes +) 0.398 ,0.001 87
C-PCR6XD
b (T. cruzi/mL)6(% nymphs +) 0.456 0.006 35
C-PCR6BC (T. cruzi/mL)6(% tubes +) 0.270 0.106 37
qRT-PCR
c6XD (T. cruzi/mL)6(% nymphs +) 0.457 ,0.001 88
qRT-PCR
c6BC (T. cruzi/mL)6(% tubes +) 0.473 ,0.001 90
qRT-PCR
c6C-PCR
b (T. cruzi/mL)6(T. cruzi/mL) 0.725 ,0.001 38
qRT-PCR
c6viral load
b (T. cruzi/mL)6(RNA copies/mL) 0.584 0.007 20
qRT-PCR
c6CD4
+ T cells
b (T. cruzi/mL)6(cells/mm
3) 20.381 0.038 30
qRT-PCR
c6CD4
+/CD8
+b (T. cruzi/mL)6(cells/mm
3) 20.484 0.007 30
aBlood culture (BC), xenodiagnosis (XD), competitive PCR (C-PCR), and quantitative real-time PCR (qRT-PCR).
bCorrelation is significant at the 0.01 level (2-tailed).
cqRT-PCR was performed only on positive S35–S36 PCR samples.
doi:10.1371/journal.pntd.0001277.t003
Figure 3. Amplification of T. cruzi DNA extracted from blood of four patients with HIV/T. cruzi coinfection (CO). Colored continuous
lines represent CO patients (4.83–142.4 parasites/mL), and black line represents the positive control, 5610
214 parasites/mL. A) Dashed lines represent
the controls without Chagas disease, and the negative controls for the reagents and room of DNA application. B) Dashed lines represent the negative
control individual without Chagas disease for each patient. Dotted lines represent the negative controls for the reagents and DNA application.
doi:10.1371/journal.pntd.0001277.g003
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could be used for diagnostic purposes. However, C-PCR is more
labor-intensive and time-consuming and requires more DNA,
post-PCR processing of the amplified products and subjective
analysis of the results.
The previous result of 41% positivity for chronic Chagas disease
by qRT-PCR [22] is similar to the results observed in our study. In
addition, qRT-PCR with the S35/S36 primers was used to measure
parasitemia in neonates with congenital Chagas disease [23]; this
analysis yielded similar data to those observed here in the RE group
compared with the CR group using satellite sequences. Those
authors reported a higher level of parasitemia (.1000 copies/mL
blood) in neonates compared with their mothers with chronic
Chagas disease (,10 copies/mL blood) [23]. In our study, the level
of parasitemia in the RE group (median 1428.90 parasites) was
higher than in the CO group (median 1.57 parasites) and CR group
(median 0.00 parasite). A previous study on the reactivation of
Chagas disease in heart transplant patients with positive Strout tests
[24] reported a lower concentration of parasites in the blood than
that shown in our study (9.07 and 468.0 parasites/mL).
Our data show that C-PCR and qRT-PCR had higher
sensitivities than the parasitological tests (xenodiagnosis and blood
culture) and confirmed the previously described higher sensitivity
of S35/S36 PCR [35–37]. Moreover, PCR takes less time (a few
hours) and has a low risk of infection, in contrast to the labor-
intensive and time-consuming parasitological tests (30–120 days),
which have high specificity but require the manipulation of live
parasites. The risk of DNA contamination in molecular tests needs
to be minimized by using negative controls at each stage of the
analysis. The risk of contamination is lower with qRT-PCR
because it employs extraction kits and excludes post-processing
PCR, although the high cost is a disadvantage.
Analyses of the demographical characteristics of the different
clinical groups showed no differences in terms of gender, but RE
patients were younger than the other groups, possibly due to the
epidemiological characteristicsof HIV-infected patients inBrazil[2].
A limitation of our study was that the small number of patients with
Chagas disease reactivation did not allow for age-matched controls.
An analysis of the level of parasitemia in different groups
represents a good strategy to monitor the host protozoan/virus
imbalance. Our data were not influenced by the lineage of the
parasite, which was similar for most of the isolates (data not
shown), as previously observed [24]. In our study, the parasite level
was lower in the CR group and higher in the CO and RE groups,
possibly due to ability of the parasite to evade the host immune
response in patients without HIV infection. Cellular immunity and
macrophage deficiencies in HIV infection could explain the
increased parasitemia observed in HIV/T. cruzi-infected patients.
The highest level of parasitemia was seen in the RE group, which
was associated with increased HIV viral load, a decreased number
of CD4
+ cells, and a decreased CD4
+/CD8
+ cell ratio; these
results confirm the failure of immune mechanisms in the RE
group. These data are corroborated by clinical studies that showed
a relationship between the reactivation of trypanosomiasis,
Figure 4. Correlation between number of parasites/mL of
blood by competitive PCR (C-PCR) and real-time PCR (qRT-
PCR). Correlation between number of T. cruzi/mL in 38 paired samples
from patients infected with HIV/T. cruzi with or without Chagas disease
reactivation. Spearman’s correlation index (rs)=20.725, P,0.001.
doi:10.1371/journal.pntd.0001277.g004
Figure 5. Correlation between the number of parasites/mL of
blood (qRT-PCR) and CD4
+/CD8
+ T cell ratio. Spearman correla-
tion index (rs)=20.484, P=0.007 by analysis of 30 samples from
patients infected with HIV/T. cruzi with and without Chagas disease
reactivation.
doi:10.1371/journal.pntd.0001277.g005
Figure 6. Correlation between number of T. cruzi/mL of blood
(qRT-PCR) and HIV RNA copies/mL of plasma). Spearman’s
correlation coefficient (rs)=0.584, P=0.007 (Analysis of 20 samples
from patients infected with HIV/T. cruzi with and without Chagas
disease reactivation). In this Figure, 8 samples were superimposed in
the lower limit of viral load and number of parasites/mL.
doi:10.1371/journal.pntd.0001277.g006
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+ counts in
peripheral blood [11].
The correlation between HIV viral load and the concentration of
parasites was demonstrated for the first time in our study, although
it has been previously suggested by the relationship observed
between an increased viral load and an increased rate of positive
xenodiagnosis in HIV/T. cruzi-infected patients [11]. These data
are also consistent with the rapid evolutionof murine leukemia virus
inmiceinfectedbyT.cruzi[38].Althoughnorelationshipwasfound
between CD8
+ cells and the concentration of parasites, their ability
to control infection via IFN-c secretion [39] has been demonstrated
previously. The strong correlation between the number of parasites
and CD4
+/CD8
+ cells suggests that both cells play a role in the
control of parasitemia. The data from a previous report [40] in
mice, which showed high parasitemia in CD4
2/CD8
+ animals and
low parasitemia and high survival in CD4+/CD8+ mice, help to
explain the results of this study.
Reactivation of chronic Chagas disease or increased parasitemia
has been reported in T. cruzi-infected patients with hematological
malignancies or autoimmune diseases receiving cytotoxic or anti-
inflammatory therapy with corticosteroids [4,24,41]. Severe
reactivation of trypanosomiasis has been described in about 20%
[11] of patients infected with HIV (although these data are
possibly overestimated by the inclusion of one referral center). In
these cases, if treatment is delayed for at least 30 days, the
mortality rate of such patients is 80%, but mortality decreases to
20% for patients treated within 30 days, indicating that earlier
diagnosis and treatment increase patient survival [8–16].
One of the limitations of this study is the cross-sectional design,
which does not allow for an investigation of the evolution of
parasitemia. Another limitation is the low number of HIV-infected
patients with Chagas disease reactivation, which constitutes an
important challenge for prospective studies. Nevertheless, we
observed that the high levels of parasitemia seen in the majority of
HIV-infected patients with reactivation were not found in
coinfected patients without reactivation.
Considering the imbalance of host-parasite interactions in
HIV/T. cruzi-coinfected patients and the fact that HIV infection
might favor parasite growth by itself, therapy might be considered
in these coinfected patients on the basis of high parasitemia and
low CD4
+ count and decreased CD4
+/CD8
+ ratio, even though
symptoms were absent. The adverse effects of the drugs, previous
immunosuppression and the immunosuppressive effects of Chagas
disease, poor surveillance against neoplasia and the therapy
efficacy, which is lower in the presence of low levels of parasitemia,
must be taken into consideration when recommending universal
therapy for any coinfected patient.
We propose that prospective multicenter studies are warranted
to address important questions regarding the management of
HIV/T. cruzi coinfection, including determining why Chagas
disease reactivation occurs in some individuals with lower levels of
parasitemia, characterizing the influence of parasite lineage and
immune responses on reactivation, and evaluating the outcome of
initiating therapy on the basis of serology [42] versus treating with
pre-emptive therapy (parasitemia versus uniquely or persistently
high levels of parasitemia).
Finally, in the present study, we demonstrated for the first time
that qRT-PCR shows different levels of parasitemia in groups of
HIV/T. cruzi-infected patients with and without Chagas disease
reactivation. The highest concentrations of parasites were found in
the latter, followed by coinfected patients and, finally, patients with
chronic Chagas disease. We propose that this new test be
evaluated under standardized conditions in prospective controlled
studies to determine the importance of parasitemia (persistent
and/or increased) as a criterion for initiating pre-emptive
therapy in chronic Chagas disease patients with HIV infection
or immunosuppression. The association of increased parasitemia
with increased viral HIV load and a decreased CD4
+ count and
CD4
+/CD8
+ ratio in peripheral blood suggests that these could be
analyzed as cofactors of increased parasitemia to further support
any intervention.
In addition, this association (increased parasitemia, increased
HIV viral load and decreased number of CD4
+ cells/mm
3 and
decreased CD4
+/CD8
+ ratio) reinforces the need to monitor
parasitemia using quantitative methods to determine when to start
therapy for the better management of Chagas disease in patients
with immunosuppression.
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